Ian R Marsh
Overview
Explore the profile of Ian R Marsh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reyes-Gonzalez J, Rajkumar H, Lee W, Baidoo K, Edinger R, Diehl G, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39911068
Radiopharmaceutical therapy (RPT) is a promising approach to treating solid tumors, but therapeutic advances are impeded by the lack of broadly expressed targets and shared molecular vulnerability across different tumor...
2.
Su L, Huang E, Miles D, Farjam R, Marsh I, Li Q, et al.
J Appl Clin Med Phys
. 2024 Aug;
25(10):e14485.
PMID: 39190567
Purpose: A single treatment planning system (TPS) model for matched linacs provides flexible clinical workflows from patient treatment to intensity-modulated radiation therapy (IMRT) quality assurance (QA) measurement. Since general guidelines...
3.
Adam D, Grudzinski J, Marsh I, Hill P, Cho S, Bradshaw T, et al.
Int J Radiat Oncol Biol Phys
. 2024 Feb;
119(4):1275-1284.
PMID: 38367914
Purpose: Targeted radiopharmaceutical therapy (RPT) in combination with external beam radiation therapy (EBRT) shows promise as a method to increase tumor control and mitigate potential high-grade toxicities associated with re-treatment...
4.
Marsh I, Li C, Grudzinski J, Jeffery J, Longhurst C, Adam D, et al.
Cancer Biother Radiopharm
. 2023 Apr;
38(7):458-467.
PMID: 37022739
Delivery of radiotherapeutic dose to recurrent head and neck cancer (HNC) is primarily limited by locoregional toxicity in conventional radiotherapy. As such, HNC patients stand to benefit from the conformal...
5.
Potluri H, Ferreira C, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle J, et al.
J Immunother Cancer
. 2022 Aug;
10(8).
PMID: 36002185
Background: Systemic radiation treatments that preferentially irradiate cancer cells over normal tissue, known as targeted radionuclide therapy (TRT), have shown significant potential for treating metastatic prostate cancer. Preclinical studies have...
6.
Adam D, Grudzinski J, Bormett I, Cox B, Marsh I, Bradshaw T, et al.
Med Phys
. 2022 May;
49(8):5491-5503.
PMID: 35607296
Purpose: Approximately 50% of head and neck cancer (HNC) patients will experience loco-regional disease recurrence following initial courses of therapy. Retreatment with external beam radiotherapy (EBRT) is technically challenging and...
7.
Magee K, Marsh I, Turek M, Grudzinski J, Aluicio-Sarduy E, Engle J, et al.
PLoS One
. 2021 Aug;
16(8):e0255798.
PMID: 34383787
Rationale: Murine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present...
8.
Patel R, Hernandez R, Carlson P, Grudzinski J, Bates A, Jagodinsky J, et al.
Sci Transl Med
. 2021 Jul;
13(602).
PMID: 34261797
Molecular and cellular effects of radiotherapy on tumor microenvironment (TME) can help prime and propagate antitumor immunity. We hypothesized that delivering radiation to all tumor sites could augment response to...
9.
Jagodinsky J, Jin W, Bates A, Hernandez R, Grudzinski J, Marsh I, et al.
Theranostics
. 2021 May;
11(13):6120-6137.
PMID: 33995649
Clinical interest in combining targeted radionuclide therapies (TRT) with immunotherapies is growing. External beam radiation therapy (EBRT) activates a type 1 interferon (IFN1) response mediated via stimulator of interferon genes...
10.
Clark P, Sriramaneni R, Bates A, Jin W, Jagodinsky J, Hernandez R, et al.
Radiat Res
. 2021 Apr;
195(6):522-540.
PMID: 33826741
Brain metastases develop in over 60% of advanced melanoma patients and negatively impact quality of life and prognosis. In a murine melanoma model, we previously showed that an in situ...